We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

229 hedge funds and large institutions have $2.1B invested in Syndax Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 83 increasing their positions, 80 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $30M | Put options by funds: $14.4M

35% more capital invested

Capital invested by funds: $1.56B → $2.1B (+$543M)

22% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 27

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

4% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 80

1% more funds holding

Funds holding: 227 → 229 (+2)

2.44% less ownership

Funds ownership: 117.38% → 114.94% (-2.4%)

Holders
229
Holders Change
+2
Holders Change %
+0.88%
% of All Funds
2.78%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.13%
New
33
Increased
83
Reduced
80
Closed
27
Calls
$30M
Puts
$14.4M
Net Calls
+$15.6M
Net Calls Change
+$3.08M

Top Buyers

1
HRCM
Hood River Capital Management
Florida
+$40.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19M
3
Bank of America
Bank of America
North Carolina
+$17.7M
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$13.8M
5
State Street
State Street
Massachusetts
+$13M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$51M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.4M
3
Millennium Management
Millennium Management
New York
-$17.3M
4
UBS Group
UBS Group
Switzerland
-$16.7M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
101
VOYA Investment Management
Georgia
$1.13M -$517K -29,625 -36%
TC
102
TwinBeech Capital
New York
$1.11M +$150K +8,606 +19%
Millennium Management
103
Millennium Management
New York
$1.09M -$17.3M -994,519 -95%
PWM
104
Palumbo Wealth Management
New York
$1.08M +$896K +51,368 New
MIM
105
MetLife Investment Management
New Jersey
$1.04M – – –
Mirae Asset Global ETFs Holdings
106
Mirae Asset Global ETFs Holdings
Hong Kong
$1.03M +$38.5K +2,204 +5%
Tudor Investment Corp
107
Tudor Investment Corp
Connecticut
$996K -$48.2K -2,763 -6%
Man Group
108
Man Group
United Kingdom
$938K -$2.27M -130,313 -74%
CC
109
Clearline Capital
New York
$912K +$161K +9,236 +27%
Assenagon Asset Management
110
Assenagon Asset Management
Luxembourg
$877K -$30.4M -1,742,402 -98%
Los Angeles Capital Management
111
Los Angeles Capital Management
California
$874K +$176K +10,066 +18%
IIM
112
INTECH Investment Management
Florida
$857K +$121K +6,918 +20%
State of Wisconsin Investment Board
113
State of Wisconsin Investment Board
Wisconsin
$856K -$167K -9,569 -19%
FRM
114
Fox Run Management
Connecticut
$847K +$81.1K +4,646 +13%
Janus Henderson Group
115
Janus Henderson Group
United Kingdom
$827K – – –
SC
116
SummitTX Capital
Texas
$822K -$1.07M -61,459 -61%
WB
117
WesBanco Bank
West Virginia
$777K +$645K +37,000 New
LPC
118
Lion Point Capital
New York
$756K -$331K -19,000 -35%
Wellington Management Group
119
Wellington Management Group
Massachusetts
$749K -$45.3K -2,596 -7%
DekaBank Deutsche Girozentrale
120
DekaBank Deutsche Girozentrale
Germany
$710K – – –
VIA
121
Virtus Investment Advisers
Connecticut
$705K +$399K +22,885 +215%
Carson Wealth (CWM LLC)
122
Carson Wealth (CWM LLC)
Nebraska
$670K +$187K +10,737 +51%
DnB Asset Management
123
DnB Asset Management
Norway
$625K +$113K +6,466 +28%
Cerity Partners
124
Cerity Partners
New York
$606K +$36.3K +2,082 +8%
Dimensional Fund Advisors
125
Dimensional Fund Advisors
Texas
$595K -$1.63M -93,155 -77%
3 4
5
6 7

SNDX Hedge Fund Activity: Q4 2025 in Review

229 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2025, worth a combined $2.1B — up 35% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new SNDX positions and 27 closed out — a net gain of 6 holders — while 83 added to existing stakes and 80 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $40.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $51M sold.

  • 229 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2025, up from 227 in Q3 2025.
  • Funds reported $2.1B of Syndax Pharmaceuticals stock for Q4 2025, up 35% quarter-over-quarter.
  • 33 funds opened new Syndax Pharmaceuticals positions in Q4 2025 and 27 closed out, a net change of +6 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2025 was Hood River Capital Management, an estimated $40.4M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $51M sold.

Based on aggregated 13F filings for Q4 2025.